Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:NNOX NASDAQ:PLSE NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$20.81-2.1%$22.00$19.10▼$29.55$995.21M1.76389,948 shs394,039 shsNNOXNano-X Imaging$4.60-2.3%$5.17$3.75▼$11.00$272.14M1.951.13 million shs1.38 million shsPLSEPulse Biosciences$14.75-1.8%$15.81$13.50▼$25.00$1.01B1.6147,924 shs159,304 shsTNDMTandem Diabetes Care$15.40-1.2%$18.30$14.31▼$47.60$1.04B1.481.65 million shs1.39 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-2.12%-7.84%-8.53%-17.65%-13.36%NNOXNano-X Imaging-2.34%-11.54%-13.70%-10.68%-46.64%PLSEPulse Biosciences-1.80%-1.21%-3.72%-14.19%-1.40%TNDMTandem Diabetes Care-1.16%-3.08%-9.84%-28.31%-58.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.7845 of 5 stars3.53.00.00.02.12.50.6NNOXNano-X Imaging2.1928 of 5 stars3.63.00.00.02.10.00.6PLSEPulse Biosciences3.9045 of 5 stars3.51.00.04.21.94.20.0TNDMTandem Diabetes Care3.5899 of 5 stars3.21.00.04.93.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.0048.97% UpsideNNOXNano-X Imaging 3.25Buy$9.50106.52% UpsidePLSEPulse Biosciences 3.00Buy$22.0049.15% UpsideTNDMTandem Diabetes Care 2.36Hold$32.71112.43% UpsideCurrent Analyst Ratings BreakdownLatest NNOX, TNDM, BLFS, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.007/14/2025NNOXNano-X ImagingLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.006/6/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/23/2025NNOXNano-X ImagingD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/22/2025NNOXNano-X ImagingAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/13/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$87.76M11.34$0.12 per share173.53$7.52 per share2.77NNOXNano-X Imaging$11.28M23.56N/AN/A$3.27 per share1.41PLSEPulse Biosciences$700K1,417.48N/AN/A$1.87 per share7.89TNDMTandem Diabetes Care$982.95M1.04N/AN/A$4.01 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/7/2025 (Estimated)NNOXNano-X Imaging-$53.52M-$0.90N/AN/AN/A-472.19%-30.92%-27.73%8/19/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/12/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest NNOX, TNDM, BLFS, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025NNOXNano-X Imaging-$0.15N/AN/AN/A$3.20 millionN/A8/12/2025Q2 2025PLSEPulse Biosciences-$0.26N/AN/AN/AN/AN/A8/7/2025Q2 2025BLFSBioLife Solutions-$0.02N/AN/AN/A$23.71 millionN/A8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40N/AN/AN/A$238.39 millionN/A5/22/2025Q1 2025NNOXNano-X Imaging-$0.23-$0.21+$0.02-$0.21$3.98 million$3.00 million5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ANNOXNano-X ImagingN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.014.733.74NNOXNano-X ImagingN/A5.305.16PLSEPulse BiosciencesN/A15.5815.58TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%NNOXNano-X Imaging21.49%PLSEPulse Biosciences76.95%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%NNOXNano-X Imaging7.74%PLSEPulse Biosciences71.50%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.84 million46.78 millionOptionableNNOXNano-X Imaging19057.78 million53.31 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableNNOX, TNDM, BLFS, and PLSE HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Position Increased by Bayforest Capital LtdAugust 1 at 5:53 AM | marketbeat.comTandem Diabetes Care Announces Upcoming Conference ParticipationJuly 31 at 4:05 PM | businesswire.com1 of Wall Street’s Favorite Stock to Research Further and 2 Facing HeadwindsJuly 31 at 3:48 PM | finance.yahoo.comTandem Diabetes Care (TNDM) Expected to Announce Earnings on WednesdayJuly 31 at 7:06 AM | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?July 30 at 11:06 AM | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 5.8% - Here's What HappenedJuly 29, 2025 | marketbeat.comGSA Capital Partners LLP Takes $2.50 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 29, 2025 | marketbeat.comWhy Tandem Diabetes (TNDM) Stock Is Trading Up TodayJuly 28, 2025 | msn.comTandem Diabetes Care issues insulin pump warning over potential speaker malfunctionJuly 26, 2025 | massdevice.com1492 Capital Management LLC Makes New $430,000 Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24, 2025 | marketbeat.comEnvestnet Asset Management Inc. Buys 64,467 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Cerity Partners LLCJuly 22, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 12-Month Low - Time to Sell?July 21, 2025 | marketbeat.comDown 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)July 21, 2025 | zacks.comGW&K Investment Management LLC Purchases 740,499 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 21, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by AnalystsJuly 20, 2025 | marketbeat.comHussman Strategic Advisors Inc. Makes New $1.21 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 19, 2025 | marketbeat.comTandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shiftsJuly 17, 2025 | investing.comWhat is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?July 16, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What HappenedJuly 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNNOX, TNDM, BLFS, and PLSE Company DescriptionsBioLife Solutions NASDAQ:BLFS$20.81 -0.45 (-2.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.80 0.00 (-0.02%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Nano-X Imaging NASDAQ:NNOX$4.60 -0.11 (-2.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.66 +0.07 (+1.41%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.Pulse Biosciences NASDAQ:PLSE$14.75 -0.27 (-1.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.73 -0.02 (-0.14%) As of 08/1/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Tandem Diabetes Care NASDAQ:TNDM$15.40 -0.18 (-1.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.69 +0.29 (+1.88%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
